Case Report: Cutaneous T-cell lymphoma associated with biologic therapy: three cases and a literature review

Tingting Li, Guanyu Wang, Chunlei Zhang, Wenhui Wang, Chunting Li, Yimeng WangFrontiers in Medicine 2025 · DOI

This case report and literature review, published in Frontiers in Medicine, explores a troubling diagnostic intersection: the "masquerade" of Cutaneous T-cell lymphoma (CTCL) as Atopic Dermatitis (AD). The authors present three clinical cases where patients treated with modern biologics for eczema were later found to have lymphoma, suggesting that these advanced therapies may either unmask or potentially accelerate the progression of underlying malignancy.

TL;DR

Early-stage Cutaneous T-cell lymphoma (CTCL) often perfectly mimics severe eczema, leading to frequent misdiagnosis. This paper highlights how modern biologic treatments for eczema, specifically IL-4Rα inhibitors like dupilumab, may inadvertently unmask or drive the progression of CTCL, necessitating urgent clinical vigilance and routine biopsies for refractory cases.

What Problem Does This Paper Address?

The central challenge is a "diagnostic trap." Atopic Dermatitis (AD) is a common inflammatory skin condition, while CTCL is a rare, life-threatening malignancy of T-cells. In their early stages, they are clinically and histopathologically almost indistinguishable—both present with itchy, red, scaly plaques.

With the advent of highly effective biologic therapies (like dupilumab) and JAK inhibitors for AD, clinicians are seeing a new phenomenon: patients who appear to have "refractory AD" actually have undiagnosed CTCL. The paper investigates whether these biologics are simply failing to treat a misdiagnosed cancer, or if the drugs themselves are altering the immune environment in a way that allows CTCL to flourish.

Methods

The authors employed a dual-track approach:

  1. Clinical Case Studies: They documented three specific cases (two of Mycosis Fungoides and one of Sézary Syndrome) at Peking University Third Hospital. Each patient was initially diagnosed with AD and treated with biologics (dupilumab) or JAK inhibitors (baricitinib, upadacitinib) before their condition worsened, leading to a definitive CTCL diagnosis via skin biopsy, immunohistochemistry, and PET/CT scans.
  2. Literature Review: They conducted a systematic search of PubMed, MEDLINE, and Embase (up to December 2024), identifying 19 studies involving 31 patients who experienced CTCL onset or progression following biologic therapy for AD.

Datasets

While not a computational study, the "dataset" consists of the synthesized clinical data from:

  • The 3 new cases presented by the authors.
  • 31 patients from the literature review (17 males, 14 females; mean age ~55 years).
  • Treatment distribution: 87.10% of the reviewed cases were treated with dupilumab.

Key Insights and Ideas

  • The "Paradoxical Worsening" Red Flag: A critical insight is that if a patient’s "eczema" worsens or fails to respond to dupilumab, it should be considered a primary indicator for CTCL. In many cases, skin lesions actually improved once the biologic was discontinued.
  • The Molecular Tug-of-War: The authors discuss a potential mechanism for how dupilumab might drive CTCL. By inhibiting the IL-13Rα1 receptor to stop inflammation, the body may upregulate the IL-13Rα2 receptor. This specific receptor is associated with tumorigenesis and can stimulate cell proliferation (via cyclin-D1), potentially fueling the growth of malignant T-cells.
  • The JAK Inhibitor Connection: While dupilumab is the primary focus, the paper notes that JAK inhibitors (like upadacitinib) might also contribute to CTCL progression by dysregulating the JAK3-STAT3 signaling pathway, a known factor in lymphoma development.
  • Demographic Clues: The authors emphasize that "late-onset" eczema—patients developing severe symptoms in middle or old age without a childhood history of allergies—should be treated with extreme suspicion for CTCL.

Key Results

  • Case Outcomes: All three local cases were eventually correctly diagnosed with CTCL (Stages IB to IVA2) after failing biologic therapy. Following the switch to oncology-focused treatments (methotrexate, phototherapy, etc.), patients showed significant improvement.
  • Literature Synthesis: Among the 31 reviewed cases, Mycosis Fungoides (MF) was the most common subtype (77.78%).
  • Mortality: The review found that 12.90% of patients died of the disease following the "unmasking" by biologic therapy, highlighting the high stakes of delayed diagnosis.

Limitations and Future Work

The authors acknowledge several limitations:

  • Sample Size: The study relies on a small number of cases and a relatively small pool of literature, which limits the ability to generalize the findings.
  • Causality vs. Correlation: It remains difficult to prove whether the biologics caused the lymphoma or if the lymphoma was already present but "masked" by the inflammatory symptoms of AD.
  • Lack of Control Groups: As a retrospective review and case series, there is no control group to compare the incidence of CTCL in AD patients not receiving biologics.

Future Work: The authors call for larger, prospective studies to clarify the relationship between JAK inhibitors and CTCL and suggest that "skin biopsy" should become a routine requirement for any patient with refractory eczematous presentations before or during biologic therapy.

Summary updated

Abstract

Cutaneous T-cell lymphoma (CTCL) often presents with early-stage clinical features indistinguishable from atopic dermatitis (AD), posing significant diagnostic challenges. Recent studies have highlighted cases where patients initially diagnosed with AD and treated with biologic agents were subsequently reclassified as having CTCL, though the nature of this relationship remains poorly understood. In this report, we present two cases of mycosis fungoides and one case of Sézary syndrome (SS), all initially diagnosed as AD and treated with biologic agents, including dupilumab. Furthermore, we conducted a literature review exploring potential associations between AD, biologic agents, and CTCL. Our objective is to improve clinicians' ability to differentiate between AD and CTCL and to provide evidence supporting a possible association between biologic treatments and CTCL. Our findings highlight the need for heightened clinical vigilance and the routine use of skin biopsy in refractory eczematous presentations.
BibTeX
@inproceedings{li2025case,
  author = {Tingting Li and Guanyu Wang and Chunlei Zhang and Wenhui Wang and Chunting Li and Yimeng Wang},
  title = {{Case Report: Cutaneous T-cell lymphoma associated with biologic therapy: three cases and a literature review}},
  booktitle = {Frontiers in Medicine},
  year = {2025},
  doi = {10.3389/fmed.2025.1544912},
}
Figure